CRISPR-Cas9 base editing to render CaMKIId phosphoresistant improves survival and cardiac function in heart failure
We ablated the autophosphorylation site of CaMKIId (T287) using CRISPR-Cas9 adenine base editing technology. Ten-weeks old C57Bl6 wildtype and CaMKIId T287A mice were subjected to either sham or severe transverse aortic constriction (sTAC) surgery (WT-Sham, WT-sTAC, T287A-Sham, T287A-sTAC; 3 biological replicates per group). Two weeks after the surgery, hearts were harvested for RNA isolation and subsequent bulk RNA sequencing and gene expression profiling analysis. Overall design: Comparative gene expression profiling analysis of RNA-seq data for WT-Sham, WT-sTAC, T287A-Sham, and T287A-sTAC.